News Coverage

Pain in the brain? Trigemina seeking to break the barrier

Bioworld Today – No matter what the cause – cluster headaches, migraines, cancer, nerve damage, temporomandibular joint disorder, trigeminal neuralgia or another disorder – chronic head pain remains among the most vexing of medical conditions for patients and the most daunting of challenges for scientists. Over-the-counter remedies that may help acute conditions often are ineffective […]

Trigemina expands Phase II trial of TI-001 for chronic migraine

Pharmaceutical Business Review – US-based biopharmaceutical firm Trigemina has expanded its Phase II clinical trial for TI-001, intranasal oxytocin, beyond Chile to include sites in Brisbane and Adelaide, Australia. The Phase II TRIG-05 trial is assessing TI-001, an investigational, nasally-delivered oxytocin therapeutic currently being examined to determine its efficacy, tolerability, and safety in chronic migraine […]

Intranasal Oxytocin-Based Drug Effective as Migraine Treatment

Migraine.com – According to a small research study presented at the 2013 International Headache Congress, a hormone called oxytocin may be an effective treatment for Migraine. Oxytocin is a hormone that plays a role in neuromodulation in the brain. It’s often referred to as the love hormone because of the role it plays in bonding […]

‘Trust Hormone’ May Provide Migraine Relief

Headaches.org – Relief for people who suffer from chronic migraine may be derived from the hormone oxytocin, according to information presented at the International Headache Congress during June in Boston. In the study of 40 participants, those who received an intranasal dose of oxytocin reported significant pain relief from 2 to 4 hours later. Sixty-four […]

Therapy Utilizing Intranasal Oxytocin Looks Promising for Migraine

Medscape – BOSTON — Results of a small study of an intranasal version of the hormone oxytocin indicate that the agent may be helpful in the management of chronic migraine. The single-dose, placebo-controlled, double-blind study found the agent, currently called TI-001, to be safe and highly effective. The study, which was presented here at the 2013 […]

Trigemina Secures $4,500,000 Series A Funding Round

Xconomy – Trigemina, Inc. exploits a newly discovered pathway for targeting the central nervous system, enabling vast new opportunities for treating acute and chronic pain. Proceeds for the Series A-1 round will be used to fund the completion of the Phase II TRIG-05 clinical trial evaluating the Company’s lead drug candidate, TI-001, an intranasal oxytocin […]

Migraine relief in sight

San Francisco Business Times – Seven years, $8 million and an ocean between clinical trials, two brothers and their small East Bay biotech company want to turn a reformulated hormone used to induce labor into a treatment for chronic migraines.